Advances in Chronic Kidney Disease
Volume 13, Issue 4 , Pages 428-432 , October 2006

Obesity: A Problem of Darwinian Proportions?

  • Suzanne Watnick

      Affiliations

    • Division of Nephrology and Hypertension, Department of Medicine, Oregon Health and Science University, Portland, OR
    • Portland VA Medical Center, Portland, OR.
    • Corresponding Author InformationAddress correspondence to Suzanne Watnick, MD, Portland VA Medical Center, 3710 SW US Veterans’ Hospital Drive, P3NEPH, Portland, OR 97239.

References 

  1. Snyder L, Leffler C. Ethics manual, fifth edition. Ann Intern Med. 2005;142:560–582
  2. National Center for Health Statistics. CDC Web site. Available at: http://www.cdc.gov/nccdphp/dnpa/obesity/index.htm
  3. Hubert H, Feilab M, McNamaara P, et al. Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67:968–977
  4. Wilson P, D’Agostino R, Sullivan L, et al. Overweight and obesity as determinants of cardiovascular risk: The Framingham experience. Arch Intern Med. 2002;162:1867–1872
  5. Calle E, Thun M, Petrilli J, et al. Moby-mass index and mortality in a prospective cohort of US adults. N Engl J Med. 1999;341:1097–1105
  6. McGee D. Body mass index and mortality: A meta-analysis based on person-level data from twenty-six observational studies. Ann Epidemiol. 2005;15:87–97
  7. Tsai S, Donnelly R, Wendt J. Obesity and mortality in a prospective study of a middle-aged industrial population. J Occup Environ Med. 2006;48:22–27
  8. Abrass CK. Obesity: What does it have to do with kidney disease?. J Am Soc Nephrol. 2004;15:2768–2772
  9. Bagby S. Obesity-initiated metabolic syndrome and the kidney: A recipe for chronic kidney disease?. J Am Soc Nephrol. 2004;15:2775–2791
  10. Hsu C, McCulloch C, Iribarren C, et al. BMI and risk for end-stage renal disease. Ann Intern Med. 2006;144:21–28
  11. Kramer H, Luke A, Bidani A, et al. Obesity and prevalent and incident CKD: The Hypertension Detection and Follow-Up Program. Am J Kidney Dis. 2005;46:587–594
  12. Glenn McGee: Breaking bioethics on our expanding waistline. Posted 8-25-1999. Available at: http://www.bioethics.net/articles.php?viewCat=2&articleId=91]_bioethics.net
  13. General Accounting Office. School Lunch Program: Efforts Needed to Improve Nutrition and Encourage Healthy Eating. Washington DC: U.S. Government Printing Office; 2004;GAO 03-506
  14. Trust for America’s Health. F As in Fat: How Obesity Policies Are Failing America. Washington DC: TFAH; 2004;
  15. Joseph S: Fettke v McDonald’s Corp. Press release. Posted 2-11-2005. Available at: http://www.bantransfat.com
  16. Gostin L. In: Fast and supersized: Is the answer to diet by fiat? (Hastings Center Report). 2005;p. 12–13
  17. Aristotle . The Doctrine of the Mean. translator In:  Ross WD editors. Nichomachean Ethics. Oxford: Clarendon Press; 1908;
  18. Grundy S. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrin Metab. 2004;89:2595–2600
  19. The shape of things to come. The Economist. 2003;369:11
  20. Jeffcoate W. Obesity is a disease: Food for thought. Lancet. 1998;351:903–904
  21. Williams GC, Nesse RM. The dawn of Darwinian medicine. Q Rev of Biol. 1991;66:1–22
  22. National Kidney Foundation National Kidney Foundation home page. Available at: http://www.kidney.org/kidneydisease/ckd/index.cfm. Accessed April 10, 2006.
  23. de Francisco A, Fresnedo G, Palomar R, et al. The renal benefits of a healthy lifestyle. Kidney Int Dec. 2005;(suppl 99):S2–S6Dec
  24. Praga M, Hernandez E, Andres A, et al. Effects of body weight loss and captopril treatment on proteinuria associated with obesity. Nephron. 1995;70:35–41
  25. Berchtold P, Sims EA, Horton ES, et al. Obesity and hypertension: Epidemiology, mechanisms, treatment. Biomed Pharmacother. 1983;37:251–258
  26. Meloni C, Tatangelo P, Cipriani S, et al. Adequate protein dietary restriction in diabetic and nondiabetic patients with chronic renal failure. J Ren Nutr. 2004;14:208–213
  27. Freidman A. Adiposity in dialysis: Good or bad?. Semin Dial. 2006;19:136–140
  28. Port FK, Ashby VB, Dhingra RK, et al. Dialysis dose and body mass index are strongly associated with survival in hemodialysis patients. J Am Soc Nephrol. 2002;13:1061–1066
  29. Wolfe RA, Ashby VB, Daugirdas JT, et al. Body size, dose of hemodialysis, and mortality. Am J Kidney Dis. 2000;35:80–88
  30. Leavey SF, McCullough K, Hecking E, et al. Body mass index and mortality in “healthier” as compared with “sicker” haemodialysis patients: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2001;16:2386–2394
  31. Glanton CW, Hypolite IO, Hshieh PB, et al. Factors associated with improved short term survival in obese end stage renal disease patients. Ann Epidemiol. 2003;13:136–143
  32. Johansen K, Young B, Kaysen G, et al. Association of body size with outcomes among patients beginning dialysis. Am J Clin Nutr. 2004;80:324–332
  33. Kalantar-Zadeh K, Abbott K, Salahudeen A, et al. Survival advantages of obesity in dialysis patients. Am J Clin Nutr. 2005;81:543–554
  34. Plantinga LC, Jaar BG, Fink NE, et al. Frequency of patient-physician contact in chronic kidney disease care and achievement of clinical performance targets. Int J Qual Health Care. 2005;17:115–121
  35. Edelstein L. The Hippocratic Oath: text, translation and interpretation. In:  Temkin O,  Temkin CL editor. Ancient Medicine: Selected Papers of Ludwig Edelstein. Baltimore, MD: Johns Hopkins University Press; 1967;p. 3–64
  36. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341:1725–1730
  37. Glanton CW, Kao T, Cruess D, et al. Impact of renal transplantation on survival in end-stage renal disease patients with elevated body mass index. Kidney Int. 2003;63:647–653
  38. Van den Ham EC, Kooman JP, Christiaans MH, et al. Weight changes after renal transplantation: A comparison between patients on 5-mg maintenance steroid therapy and those on steroid-free immunosuppressive therapy. Transplant Int. 2003;16:300–306
  39. In:  Levinsky NG editors. Ethics and the Kidney. New York: Oxford University Press; 2001;

PII: S1548-5595(06)00109-1

doi: 10.1053/j.ackd.2006.07.005

Advances in Chronic Kidney Disease
Volume 13, Issue 4 , Pages 428-432 , October 2006

Article Tools

* Image Usage & Resolution